Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation

Coupling engineered biomaterials and patient-specific sera provides new insights into post-surgical cell responses

Go to the profile of Greg Hudalla
Oct 24, 2019
0
0

Polystyrene as substrate and bovine serum albumin as feedstock have long been the cell culture workhorses in our quest to understand biological mechanisms in health and disease. Yet, neither really resembles the biological source material they are intended to supplant, raising questions as to what we’ve been missing. A recent report by Aguado and colleagues in Science Translational Medicine [1] shows how combining engineered hydrogel substrates and patient-derived serum can provide new understanding of myofibroblast deactivation following aortic valve replacement.

This work started with a hypothesis, namely, that the efficacy of transcatheter aortic valve replacement (i.e., “TAVR”) stems from a change in serum factors released during the post-implantation inflammatory response. TAVR is used clinically to treat aortic valve stenosis, a disease in which aberrant fibrosis and/or calcification of aortic valve leaflets leads to heart failure. Understanding how patients respond to TAVR has significant implications regarding overall patient outcomes after the procedure.

Aortic valve stenosis is characterized by chronic activation of fibroblasts into myofibroblasts that drive tissue stiffening. TAVR has been shown to promote remodeling of fibrotic cardiac tissue and reduce activation of myofibroblasts; however, the mechanism by which implantation of an artificial valve drives this response was unknown. 

To close this gap, Aguado teamed up with cardiologists and experts in fibrosis (Schuetze, Sucharov and McKinsey), biologists (Ceccato and Leinwand), biostatisticians (Tan), geneticists (Taylor), and fellow bioengineers (Grim, Walker, Cox, and Anseth). 

The team first screened pre-TAVR and post-TAVR patient serum to identify factors that are up- or down-regulated, and sought to test the role of prominent factors in mediating valvular and cardiac myofibroblast activation and deactivation. The practical challenge here is that conventional tissue culture polystyrene substrates induce rampant myofibroblast activation. To address this, they relied on hydrated polymeric gels developed in the Anseth lab, which have stiffness that is comparable to healthy and diseased valve and cardiac tissue. Their results demonstrate that post-TAVR sera can drive myofibroblast deactivation, but not for every patient tested (Figure 1). Interestingly, levels of myofibroblast deactivation correlated with key echocardiography measures of patient disease severity, thus providing a clinically relevant in vitro model to evaluate patient responses to TAVR. The team also observed sex-dependent differences in myofibroblast deactivation by post-TAVR serum, which corroborate sex-specific TAVR outcomes observed in the clinic. 

Figure 1. Post-TAVR sera deactivates valvular interstitial cells (VIC) and ventricular fibroblasts (ARVF)

Moving forward, the team envisions that coupling engineered cell culture substrates with patient-derived sera will foster an era of “precision biomaterials” [2] that provide new insights into cell responses that underlie healthy versus disease states.  

References

[1] Aguado, B.A. et al, “Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation” Sci Trans Med 2019 DOI: 10.1126/scitranslmed.aav3233

[2] Aguado, B.A. et al, “Engineering precision biomaterials for personalized medicine” Sci Trans Med 2018 DOI: 10.1126/scitranslmed.aam8645 

Go to the profile of Greg Hudalla

Greg Hudalla

Associate Professor, University of Florida

self-assembled biomaterials; protein engineering; lectin-glycan interactions

No comments yet.